참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 6-Methoxy-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-ylamine | HCID 57512866 | — |
| 반응물 | (2R)-8-chloro-4-methyl-2-phenyl-3,5-dihydro-2H-pyrido[3,2-f][1,4]oxazepine | HCID 57512880 | — |
| 시약 | Potassium Carbonate | HCID 11430 | — |
| 촉매 | Binap, (A+-)- | HCID 634876 | — |
| 촉매 | Palladium (II) acetate | HCID 4144353 | — |
| 용매 | Toluene | HCID 1140 | — |
| 생성물 | gamma-Secretase modulator 6 | HCID 49819500 | 97.77% |
반응 단계
Charged a round-bottom flask with a mixture of 6-methoxy-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine (7.6 g, 37.21 mmol), (R)-8-chloro-4-methyl-2-phenyl-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepine (10.22 g, 37.21 mmol), palladium (II) acetate (0.251 g, 1.12 mmol), rac-BINAP (1.159 g, 1.86 mmol), potassium carbonate (7.71 g, 55.82 mmol), and toluene (150 mL). The atmosphere was inerted through consecutive vacuum-nitrogen purge cycles, then heated at 120 °C for 16 hours. HPLC-UV shows <9% of starting materials remaining. Added an additional 25mg palladium acetate and 116 mg BINAP, then heating was continued for another 2 hours. HPLC-UV does not show any additional progress. The heating block was removed and the mixture was allowed to cool to room temperature. Added 300 mL dichloromethane and adjusted the pH to 2 with 2.0N aqueous HCl. Separated the phases and basified the aqueous with 1.0N aqueous sodium hydroxide. Extracted with 200 mL DCM, followed by a second extraction with 100 mL DCM. The organics were dried with magnesium sulfate and concentrated by rotary evaporator to yield EN04092-38-001 (16.1 g, 36.4 mmol, 98 %) as an amber-coloured foam.
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-f324903a1dbf436dad59daccca5918c2 |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|